Neothetics, which is developing an injectable version of an approved asthma drug to reduce belly fat, raised $65 million in an upsized IPO by offering 4.65 million shares (all primary) at $14, the midpoint of the range of $13 to $15. The company originally planned to offer 4.3 million shares. Neothetics plans to list on the NASDAQ under the symbol NEOT. Neothetics initially filed confidentially on 9/12/2014. Piper Jaffray and Guggenheim Securities acted as lead managers on the deal.
